I think buying Chewie here achieves the same aim maybe more- If things change around quick the weighting of Chewie in various Index's will help it up the way it hurt it down. This is a market-timeing play.
So Tempted Van this theme song gets me fired up- are you watching the race? I want to, never seen one before--- Did you see the prices for the hotel rooms and everything..That Seminole tribe they be booking a lifetime $$$ they own Hard Rock... (great SPAC IDEA- ROCK)
I remember the QQQ were $17, sitting with my late trading buddy saying we hit bottom. Edit: What year was that? 2002?
Moderna is a bet on a platform mRNA that can be used to combat other problems.- Moderna Announces Successful Bird Flu Vaccine Trial Moderna announced successful Phase 1 clinical trial results this week for this flu-fighting mRNA-1440. The vaccine is intended to combat Influenza Virus H10N8, a strain of bird flu which began commonly appearing in 2014. In this double blind study, Moderna reported that only three trial participants (of thirty-one) showed adverse side effects which were moderate and reversible. The company noted that this trial is showing positive outcomes in the use of mRNA vaccine technology which stimulates cell production and expression of viral antigenic proteins
News Health News Moderna sets sights on flu vaccine, starts giving shots to trial participants The Cambridge biotech is applying its mRNA platform to the vax BOSTON MA. – AUGUST 12: The Moderna vaccine sits at the ready at NEW Health on August 12, 2021 in the Boston, MA. (Staff Photo By Nancy Lane/MediaNews Group/Boston Herald) | Boston Herald PUBLISHED: April 12, 2022 at 10:52 a.m. | UPDATED: April 12, 2022 at 10:54 a.m. The Cambridge-based biotech giant that created one of the earliest and most effective COVID-19 vaccines is now looking to develop a flu shot. Moderna on Monday announced that the first trial participants have been dosed in the Phase 1/2 study of the company’s seasonal influenza vaccine candidates. The biotech is applying its messenger RNA (mRNA) platform to the flu vax. This Phase 1/2 randomized study will evaluate the safety and immune response of a single dose of mRNA-1020 or mRNA-1030 in healthy adults 18-plus in the U.S. The company intends to enroll about 560 participants in the study. “We are pleased to apply Moderna’s mRNA platform to address the longstanding design and manufacturing challenges associated with developing seasonal influenza vaccines,” said Moderna CEO Stephane Bancel. The biotech believes that they can “achieve broader immunity and higher vaccine efficacy against circulating influenza strains than traditional influenza vaccines,” he added. “… We expect that our platform’s flexibility in targeting multiple strains coupled with our ability to manufacture quickly will facilitate production of a vaccine that matches the predominant circulating influenza strain,” Bancel said.
So it all boils down to numbers these guys will have unbelievable sales for years to come.> maybe patents...
Carbone Miami’s dinner at $3,000 per person, ahead of Formula 1 Fri, May 6, 2022, 5:30 PM Carbone restaurant gears up for Miami’s big Formula 1 Grand Prix weekend, starting with opulent dinners priced at $3,000 per person.
Li-Cycle Holdings Corp. (LICY) NYSE - Nasdaq Real Time Price. Currency in USD 8.00+0.26 (+3.36%) At close: 04:00PM EDT
Van as I see it there are two big risks- less sales as Covid dies out and this 2nd QTR should show that and the political scene. The streets numbers reflect NO US order<-- Biden can't get it done. Covid funding seems frozen in the Senate, It may get tacked on to some other bill--> if you see that bill pass it's a green light for Moderna because huge US order will come. A) Buy after 2Q earn I think B) Buy when Biden gets more funding. C) Buy LT these guys are going to be around & highly profitable Working in Moderna's favor is Covid is really spiking to the point where they are now calling it a 5th wave here in NYC.~si